Listen
Japanese
Contact

News

Sawai Receives Approvals for Six Generic Drugs with 13 Strengths

Aug. 16. 2022

Osaka, Japan – August 15, 2022 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approvals by the Ministry of Health, Labour and Welfare for six generic drugs with 13 strengths. The four compounds marked with an asterisk below are approved for the first time as generics.

The list of approved products

1. Esomeprazole Capsules, Granules for Suspension

Generic name Esomeprazole Magnesium Hydrate*
Strengths Capsules: 10mg, 20mg
Granules for Suspension: 10mg, 20mg
Brand products Nexium® Capsules 10mg, 20mg, Nexium® Granules for Suspension 10mg, 20mg

2. Escitalopram Tablets, OD Tablets

Generic name Escitalopram Oxalate*
Strengths Tablets: 10mg, 20mg
OD Tablets: 10mg, 20mg
Brand products Lexapro® Tablets 10mg, 20mg

3. Ramelteon Tablets

Generic name Ramelteon
Strengths 8mg
Brand products Rozerem® Tablets 8mg

4. Tolvaptan OD Tablets

Generic name Tolvaptan
Strengths 7.5mg, 15mg
Brand products Samsca® OD Tablets 7.5mg, 15mg

5. Ibandronate Intravenous Injection Syringes

Generic name Ibandronate Sodium Hydrate*
Strengths 1mg
Brand products Bonviva® Syringes for Intravenous Injection 1mg

6. Daptomycin for Intravenous Injection

Generic name Daptomycin*
Strengths 350mg
Brand products Cubicin® IV 350mg

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.